Trigeminal Nerve Stimulation for Bleeding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective prophylactic and therapeutic solutions for controlling bleeding in various medical scenarios, including surgeries, trauma, and bleeding disorders, with existing treatments being risky, costly, or unavailable in resource-poor areas, and often associated with significant mortality rates.
Innovation Solution
The use of electrical and mechanical stimulation of the trigeminal nerve to reduce bleeding, applying frequencies between 0.1 Hz and 100 Hz for more than 10 minutes, which can be invasive or non-invasive, to control bleeding time and blood loss in surgical, traumatic, and bleeding disorder-related cases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pharmacological therapies are used to control bleeding, then hemostasis can be achieved, but the treatments are risky, costly, and associated with significant mortality rates
Solution Approach 1:
The patent replaces pharmacological chemical therapy with electrical stimulation of the trigeminal nerve to achieve hemostasis. This substitution eliminates the need for systemic medications and their associated risks, using instead a localized neuromodulation approach that activates endogenous clotting mechanisms through electrical signals to the brainstem.
Solution Approach 2:
The trigeminal nerve acts as an intermediary between the external electrical stimulation and the brainstem's hemostatic control centers. By stimulating this specific nerve pathway, the system indirectly activates the body's natural clotting mechanisms without requiring direct pharmacological intervention at the bleeding site or systemic administration of drugs.
2Reliability
If existing bleeding control methods are applied, then some hemostasis can be achieved, but the treatments are unavailable in resource-poor areas
Solution Approach 1:
The electrical stimulation device represents a low-cost, portable solution that can be deployed in resource-poor settings. Unlike expensive pharmacological therapies requiring cold chains, specialized storage, and trained administrators, the electrical stimulation system uses simple electrodes and power sources that can function in basic clinical environments without sophisticated infrastructure.
Solution Approach 2:
The system leverages the body's own hemostatic mechanisms rather than requiring external pharmacological agents. By activating endogenous clotting pathways through trigeminal nerve stimulation, the treatment becomes self-sustaining and does not depend on the availability of costly medications, blood products, or advanced medical supplies.
3Reliability
If conventional hemostasis treatments are used, then bleeding can be controlled in some cases, but the procedures are complex and risky
Solution Approach 1:
The patent extracts the core hemostatic control function from complex surgical interventions and pharmacological regimens, isolating it to a specific neural pathway (trigeminal nerve). This extraction allows the bleeding control mechanism to be activated through simple electrical stimulation of a single nerve, eliminating the need for complex multi-step procedures, multiple medications, or invasive surgical interventions.
Data Source
AI summary
Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.